Charles Schwab Investment Management Inc. Has $14.89 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 4.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,979,992 shares of the biotechnology company’s stock after purchasing an additional 91,998 shares during the period. Charles Schwab Investment Management Inc. owned 0.96% of BioCryst Pharmaceuticals worth $14,890,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its holdings in BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after purchasing an additional 86,571 shares in the last quarter. Principal Financial Group Inc. increased its holdings in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares in the last quarter. Fisher Asset Management LLC increased its holdings in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after purchasing an additional 481,359 shares in the last quarter. Geode Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock valued at $36,776,000 after buying an additional 127,708 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in BioCryst Pharmaceuticals by 472.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock valued at $3,776,000 after buying an additional 409,938 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BCRX. Evercore ISI increased their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price objective on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Up 0.8 %

NASDAQ:BCRX opened at $7.69 on Friday. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.50. The firm has a market capitalization of $1.61 billion, a P/E ratio of -12.61 and a beta of 1.85. The stock’s fifty day simple moving average is $8.12 and its 200-day simple moving average is $7.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. The firm’s revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.28 EPS. As a group, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.